Genzyme is touting the interim data from a head-to-head study that compares its drug Campath against Serono's Rebif for treating multiple sclerosis. Researchers claim that Campath patients demonstrated a lower rate of relapse and significantly reduced the rate of progression to disability. Campath is currently approved as a therapy for leukemia and Genzyme is pushing to expand its approval to MS. The two-year Phase II trial included 334 patients.
- see the release on the Campath trial